These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 29301830)

  • 1. Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27-Dependent Pathway.
    Bartkowiak T; Jaiswal AR; Ager CR; Chin R; Chen CH; Budhani P; Ai M; Reilley MJ; Sebastian MM; Hong DS; Curran MA
    Clin Cancer Res; 2018 Mar; 24(5):1138-1151. PubMed ID: 29301830
    [No Abstract]   [Full Text] [Related]  

  • 2. Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model.
    Chen S; Lee LF; Fisher TS; Jessen B; Elliott M; Evering W; Logronio K; Tu GH; Tsaparikos K; Li X; Wang H; Ying C; Xiong M; VanArsdale T; Lin JC
    Cancer Immunol Res; 2015 Feb; 3(2):149-60. PubMed ID: 25387892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model.
    Belcaid Z; Phallen JA; Zeng J; See AP; Mathios D; Gottschalk C; Nicholas S; Kellett M; Ruzevick J; Jackson C; Albesiano E; Durham NM; Ye X; Tran PT; Tyler B; Wong JW; Brem H; Pardoll DM; Drake CG; Lim M
    PLoS One; 2014; 9(7):e101764. PubMed ID: 25013914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
    Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
    Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-talk between 4-1BB and TLR1-TLR2 Signaling in CD8+ T Cells Regulates TLR2's Costimulatory Effects.
    Joseph AM; Srivastava R; Zabaleta J; Davila E
    Cancer Immunol Res; 2016 Aug; 4(8):708-16. PubMed ID: 27267778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers.
    Woroniecka KI; Rhodin KE; Dechant C; Cui X; Chongsathidkiet P; Wilkinson D; Waibl-Polania J; Sanchez-Perez L; Fecci PE
    Clin Cancer Res; 2020 Mar; 26(6):1349-1358. PubMed ID: 31871298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity.
    Ager CR; Reilley MJ; Nicholas C; Bartkowiak T; Jaiswal AR; Curran MA
    Cancer Immunol Res; 2017 Aug; 5(8):676-684. PubMed ID: 28674082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production.
    Curran MA; Kim M; Montalvo W; Al-Shamkhani A; Allison JP
    PLoS One; 2011 Apr; 6(4):e19499. PubMed ID: 21559358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 4-1BB Agonism Combined With PD-L1 Blockade Increases the Number of Tissue-Resident CD8+ T Cells and Facilitates Tumor Abrogation.
    Qu QX; Zhu XY; Du WW; Wang HB; Shen Y; Zhu YB; Chen C
    Front Immunol; 2020; 11():577. PubMed ID: 32391001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. According to Hepatitis C Virus (HCV) Infection Stage, Interleukin-7 Plus 4-1BB Triggering Alone or Combined with PD-1 Blockade Increases TRAF1
    Moreno-Cubero E; Subirá D; Sanz-de-Villalobos E; Parra-Cid T; Madejón A; Miquel J; Olveira A; González-Praetorius A; García-Samaniego J; Larrubia JR
    J Virol; 2018 Jan; 92(2):. PubMed ID: 29093082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EZH2 Inhibition Compromises α4-1BB-Mediated Antitumor Efficacy by Reducing the Survival and Effector Programming of CD8
    Stairiker CJ; Pfister SX; Hendrickson E; Yang W; Xie T; Lee C; Zhang H; Dillon C; Thomas GD; Salek-Ardakani S
    Front Immunol; 2021; 12():770080. PubMed ID: 34925340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma.
    Lacal PM; Atzori MG; Ruffini F; Scimeca M; Bonanno E; Cicconi R; Mattei M; Bernardini R; D'Atri S; Tentori L; Graziani G
    Pharmacol Res; 2020 Sep; 159():104957. PubMed ID: 32485280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity.
    Compte M; Harwood SL; Muñoz IG; Navarro R; Zonca M; Perez-Chacon G; Erce-Llamazares A; Merino N; Tapia-Galisteo A; Cuesta AM; Mikkelsen K; Caleiras E; Nuñez-Prado N; Aznar MA; Lykkemark S; Martínez-Torrecuadrada J; Melero I; Blanco FJ; Bernardino de la Serna J; Zapata JM; Sanz L; Alvarez-Vallina L
    Nat Commun; 2018 Nov; 9(1):4809. PubMed ID: 30442944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells.
    Mardiana S; John LB; Henderson MA; Slaney CY; von Scheidt B; Giuffrida L; Davenport AJ; Trapani JA; Neeson PJ; Loi S; Haynes NM; Kershaw MH; Beavis PA; Darcy PK
    Cancer Res; 2017 Mar; 77(6):1296-1309. PubMed ID: 28082401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment.
    Chelvanambi M; Fecek RJ; Taylor JL; Storkus WJ
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33526609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumoral CD8
    Horton BL; Williams JB; Cabanov A; Spranger S; Gajewski TF
    Cancer Immunol Res; 2018 Jan; 6(1):14-24. PubMed ID: 29097422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity.
    Qi X; Li F; Wu Y; Cheng C; Han P; Wang J; Yang X
    Nat Commun; 2019 May; 10(1):2141. PubMed ID: 31105267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case Report: An EGFR-Targeted 4-1BB-agonistic Trimerbody Does Not Induce Hepatotoxicity in Transgenic Mice With Liver Expression of Human EGFR.
    Compte M; Harwood SL; Martínez-Torrecuadrada J; Perez-Chacon G; González-García P; Tapia-Galisteo A; Van Bergen En Henegouwen PMP; Sánchez A; Fabregat I; Sanz L; Zapata JM; Alvarez-Vallina L
    Front Immunol; 2020; 11():614363. PubMed ID: 33488625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
    Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
    Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GITR-dependent regulation of 4-1BB expression: implications for T cell memory and anti-4-1BB-induced pathology.
    Lin GH; Snell LM; Wortzman ME; Clouthier DL; Watts TH
    J Immunol; 2013 May; 190(9):4627-39. PubMed ID: 23536631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.